Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III (LONG-DES-III)
NCT ID: NCT01078038
Last Updated: 2012-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
451 participants
INTERVENTIONAL
2008-06-30
2010-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cypher
Sirolimus-eluting stent
Cypher
Sirolimus-eluting stent implantation
Xience V
Everolimus-eluting stent
Xience V
Everolimus-eluting Stent implantation
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cypher
Sirolimus-eluting stent implantation
Xience V
Everolimus-eluting Stent implantation
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Significant native coronary artery stenosis (\>50% by visual estimate) with lesion length of more than 25mm, which requiring single or multiple long stent placement (\>=28mm)
* Patients with silent ischemia, stable or unstable angina pectoris, ad Non-ST-elevation myocardial infarction
* The patient or guardian agrees to the study protocol and the schedule of clinical and angiographic follow-up, and provides informed, written consent, as approved by the appropriate Institutional Review Board/Ethical Committee of the respective clinical site.
Exclusion Criteria
* An elective surgical procedure is planned that would necessitate interruption of antiplatelet drugs during the first 6 months post enrollment.
* Acute ST-segment-elevation MI or cardiogenic shock
* Terminal illness with life expectancy \<1 year
* Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
* In-stent restenosis at target vessel (either bare metal stent or drug-eluting stent segment, non-target vessel ISR is permitted)
* Patients with EF\<30%.
* Serum creatinine level \>=3.0mg/dL or dependence on dialysis.
* Patients with left main stem stenosis (\>50% by visual estimate).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CardioVascular Research Foundation, Korea
OTHER
Seung-Jung Park
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Seung-Jung Park
MD,PhD, Chairman,Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Seung-Jung Park, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Department of Medicine, Asan Medical Center, University of Ulsan College of Medicine
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sam Anyang Hospital
Anyang, , South Korea
Soonchunhyang University Bucheon Hospital
Bucheon-si, , South Korea
Busan Paik Hospital
Busan, , South Korea
St.Mary's Catholic Medical Center
Busan, , South Korea
Soonchunhyang University Cheonan Hospital
Cheonan, , South Korea
St.Mary's Catholic Medical Center
Cheongju-si, , South Korea
Gangwon National University Hospital
Chuncheon, , South Korea
Chungnam National University Hospital
Daejeon, , South Korea
Asan Medical Center
Gangneung, , South Korea
Gwangju Christian Hospital
Gwangju, , South Korea
Dongguk University Hospital
Gyongju, , South Korea
St.Mary's Catholic Medical Center
Inchon, , South Korea
Jeju Hanla Hospital
Jeju City, , South Korea
Gyeongsang Uniservity Hospital
Jinju, , South Korea
Asan Medical Center
Seoul, , South Korea
Hangang Sacred Heart Hospital
Seoul, , South Korea
Seoul Veterans Hospital
Seoul, , South Korea
St.Mary's Catholic Medical Center
Seoul, , South Korea
Ajou University Hospital
Suwon, , South Korea
Ulsan University Hospital
Ulsan, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Park DW, Kim YH, Song HG, Ahn JM, Kim WJ, Lee JY, Kang SJ, Lee SW, Lee CW, Park SW, Yun SC, Seung KB, Yang TH, Lee SG, Lee JH, Seong IW, Cheong SS, Lee BK, Lee NH, Lee SW, Lee SW, Lee K, Kim HS, Jeon DS, Kim MK, Nah DY, Tahk SJ, Park SJ. Comparison of everolimus- and sirolimus-eluting stents in patients with long coronary artery lesions: a randomized LONG-DES-III (Percutaneous Treatment of LONG Native Coronary Lesions With Drug-Eluting Stent-III) Trial. JACC Cardiovasc Interv. 2011 Oct;4(10):1096-103. doi: 10.1016/j.jcin.2011.05.024.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2008-0250
Identifier Type: -
Identifier Source: org_study_id